Skip to content Skip to sidebar Skip to footer

Aussie vaccine technology ‘promising’ but risks to COVID-19 strategy were too great: study

Australia’s homegrown COVID-19 vaccine candidate had potential but the false positives on HIV tests…

Australia’s homegrown COVID-19 vaccine candidate had potential but the false positives on HIV tests were too great a hurdle to move it into further trials, a study published this week has confirmed.

The University of Queensland vaccine was abandoned last year before phase 2 and 3 clinical trials after participants in the study returned false positive HIV test results.

At the time, secretary of the Department of Health Dr Brendan Murphy said no warnings were ignored about the possibility of false positives and it “was seen as a very, very unlikely possibility”.

“It was unfortunately an unexpectedly high rate of false positives that resulted when the data came in.

“This was very clearly known at the time and the risks were appropriately taken, and unfortunately it just became a bigger problem than anyone had anticipated.”

The team’s peer-reviewed study, released last December, was published in Lancet Infectious Diseases.

Project co-leader Associate Professor Keith Chappell said it showed 99 per cent of vaccinated participants in the study produced a neutralising immune response.

“In 75 per cent of vaccine recipients it was above the average in recovered patients, and in 38 per cent it was more than twice the average for recovered patients," Chappell said.

"Adverse events were comparable to those in the saline placebo, with the only exceptions being mild injection site pain and tenderness.”

The study also detailed how “sequences of the HIV-1 glycoprotein 41 used in the molecular clamp elicited antibodies that cross-reacted with rapid HIV diagnostic tests that included recombinant glycoprotein 41”.

Project director Professor Trent Munro said the design of the original molecular clamp excluded known antibody binding sites in order to reduce the potential but “unfortunately the antibodies registered a low response on some highly sensitive HIV tests”.

As a result, the vaccine would have the potential to impact existing HIV screening programs and could delay timely diagnosis, the study’s authors said. They added that potential misunderstandings about the issue could also add to the climate of vaccine hesitancy.

Project co-leader Professor Paul Young said he and the rest of the vaccine team understood the government’s decision to curb its candidate but added that the study showed the molecular clamp technology that underpinned the work was a “promising rapid response strategy for vaccine development”.

“The team is continuing to work on alternative clamp constructs that could be used to respond to COVID-19 in the future or other viral diseases.”

Young added that candidates that showed promise and are now in the market need to remain the immediate priority.

But when the federal government first made the announcement it was abandoning the UQ vaccine, he said the team of scientists were “devastated”.

“The last 11 months we’ve been living and breathing this particular project. It’s challenging times,” he said in December.

“But that's science.”

Leave a comment